Furthermore, higher levels of CCL3, CCL4 and CXCL10, independent of sex, age, FAB phenotype, patient status and risk molecular, were associated with the poor outcome of AML patients recruited in our study by Cox regression analysis. This evidence concerns the gene CXCL10 and acute myeloid leukemia.